NEW
YORK, Sept. 7, 2022 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of TG
Therapeutics, Inc..
Shareholders who purchased shares of TGTX during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/tg-therapeutics-inc-loss-submission-form/?id=31372&from=4
CLASS PERIOD: January 15,
2020 to May 31, 2022
ALLEGATIONS: The complaint alleges that during the class
period, Defendants issued materially false and/or misleading
statements and/or failed to disclose that: (i) clinical trials
revealed significant concerns related to the benefit-risk ratio and
overall survival data of the Company's therapeutic product
candidates, Ublituximab and Umbralisib; (ii) accordingly, it was
unlikely that the Company would be able to obtain approval from the
U.S. Food and Drug Administration of the Umbralisib marginal zone
lymphoma and follicular lymphoma New Drug Application, the
Biologics License Application for Ublituximab in combination with
Umbralisib, the supplemental New Drug Application for Ublituximab
in combination with Umbralisib, or the Ublituximab relapsing forms
of multiple sclerosis Biologics License Application in their
current forms; (iii) as a result, the Company had significantly
overstated Ublituximab and Umbralisib's clinical and/or commercial
prospects; and (iv) therefore, the Company's public statements were
materially false and misleading at all relevant times.
DEADLINE: September 16,
2022 Shareholders should not delay in registering for
this class action. Register your information here:
https://securitiesclasslaw.com/securities/tg-therapeutics-inc-loss-submission-form/?id=31372&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of TGTX during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is September 16, 2022. There is no
cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-tg-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-september-16-2022--nasdaq-tgtx-301618478.html
SOURCE The Gross Law Firm